TCRT — Alaunos Therapeutics Balance Sheet
0.000.00%
- $9.51m
- $7.57m
- $0.01m
Annual balance sheet for Alaunos Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 115 | 76.1 | 39.1 | 6.06 | 1.09 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 4.67 | 1.11 | 0.004 | 0.001 | 0.005 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 131 | 78.8 | 53.8 | 8.26 | 2.75 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 14.9 | 15.4 | 10.6 | 0.002 | 0 |
| Other Long Term Assets | |||||
| Total Assets | 146 | 94.9 | 64.9 | 8.26 | 2.75 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Current Liabilities | 18.4 | 16 | 24.2 | 1.96 | 0.692 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 22.4 | 36.8 | 26.4 | 1.96 | 0.692 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 124 | 58.1 | 38.6 | 6.31 | 2.06 |
| Total Liabilities & Shareholders' Equity | 146 | 94.9 | 64.9 | 8.26 | 2.75 |
| Total Common Shares Outstanding |